Interim Results | 29-Sep-2022 | 07:00 | RNS |
Positive headline results from ovarian study | 29-Sep-2022 | 07:00 | RNS |
Study using Parsortix in head and neck cancer | 28-Sep-2022 | 07:00 | RNS |
New poster presented at ASCP Meeting | 13-Sep-2022 | 07:00 | RNS |
Novel assay predicts malignancy in pelvic mass | 12-Sep-2022 | 07:30 | RNS |
Notice of Interim Results and Webcast | 01-Sep-2022 | 07:00 | RNS |
Novel insight into metastasis in NSCLC patients | 28-Jul-2022 | 07:00 | RNS |
Holding(s) in Company | 20-Jul-2022 | 14:33 | RNS |
NEW STUDY OF PARSORTIX SYSTEM IN NSCLC | 20-Jul-2022 | 07:00 | RNS |
Director/PDMR Shareholding | 19-Jul-2022 | 10:00 | RNS |
Results of Capital Raise | 15-Jul-2022 | 07:00 | RNS |
Retail Offer via PrimaryBid | 14-Jul-2022 | 17:24 | RNS |
Proposed Placing and Retail Offer | 14-Jul-2022 | 17:23 | RNS |
Issue of Equity | 08-Jul-2022 | 17:30 | RNS |
Result of 2022 Annual General Meeting | 29-Jun-2022 | 16:35 | RNS |
Currency | UK Pounds |
Share Price | 13.67p |
Change Today | -0.083p |
% Change | -0.61 % |
52 Week High | 31.35 |
52 Week Low | 9.24 |
Volume | 518,882 |
Shares Issued | 322.64m |
Market Cap | £44.09m |
RiskGrade | 312 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
12:10 | 82,692 @ 13.65p |
12:04 | 150,000 @ 13.51p |
11:58 | 5,546 @ 13.57p |
11:39 | 13,000 @ 13.59p |
11:36 | 3,631 @ 13.66p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research